Clinical trials: Hypertension, Pulmonary Artery
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- The PULSE-LHD (NCT07214376)
- Testing
- Pulmonary Artery Denervation (PADN)
- Where
- 18 sites in United States, China
- Volunteers
- 750 people
- Sponsor
- Pulnovo Medical, Inc.
Pulmonary Arterial Hypertension
Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
In an earlier study, sildenafil citrate administered to patients of PAH led to improvement in pulmonary arterial pressure, cardiac output, quality of life, and other parameters as compared to placebo.
- Trial name
- UK 92480 (NCT00878943)
- Testing
- Sildenafil citrate
- Where
- 5 sites in India
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in…
- Trial name
- NCT04576988
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 324 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension (PAH)
TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends
TRESPECT is an international, multicenter, observational registry designed to describe the real-world use, effectiveness, and tolerability of parenteral treprostinil in adults with newly diagnosed pulmonary arterial hypertension…
- Trial name
- NCT07736846
- Testing
- treprostinil
- Volunteers
- 300 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Pulmonary Arterial Hypertension
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
The goal of this observational study is to learn about the long-term development and outcomes of different treatment patterns of patients who initially participated in the TripleTRE study.
- Trial name
- TripleTRE-NIS (NCT06445673)
- Where
- 18 sites in Austria, Czechia and 7 more
- Volunteers
- 110 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Hypertension, Pulmonary
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin.
- Trial name
- NCT00643604
- Testing
- treprostinil sodium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Implantable System for Remodulin Post-Approval Study
The purpose of the Implantable System for Remodulin (ISR) Post Approval Study (PAS) is to provide evaluation and periodic reporting of the safety and effectiveness of Medtronic market-released ISR, including the catheter and the…
- Trial name
- ISR PAS (NCT03833323)
- Testing
- Implantable System for Remodulin (treprostinil)
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Arterial Hypertension
Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH
Prospective, multi-center, open-label, single-arm, Phase 3b extension study of macitentan in patients with PAH. To assess the long-term safety of macitentan in patients with pulmonary arterial hypertension (PAH) beyond treatment…
- Trial name
- NCT02112487
- Testing
- Macitentan
- Where
- 32 sites in France, Italy and 1 more
- Volunteers
- 88 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Measuring Blood Pressure in the Lung Circulation With Sonar Technology (Echo-Doppler)
This is a non-invasive study using a standard doppler echocardiographic transducer which records signals emanating from the lungs (TPD). These signals are caused by pulsation of blood vessels in the lung tissue.
- Trial name
- NCT01357746
- Testing
- Transthoracic pulmonary doppler recording
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Echosense Ltd.
Pulmonary Arterial Hypertension
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 inhibitor (PDE-5i) + parenteral treprostinil) compared to double oral therapy…
- Trial name
- TripleTRE (NCT06317805)
- Testing
- Generic treprostinil sodium + Standard of Care (Double Oral), Standard of Care - Double Oral
- Where
- 28 sites in Argentina, Austria and 10 more
- Volunteers
- 110 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension PAH
- Trial name
- TRANSCEND (NCT07612657)
- Testing
- VI-0106
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Pulmonary Arterial Hypertension
TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal Study
Theis is a prospective, multicenter, blinded, randomized sham controlled pivotal clinical trial with a crossover at 6M, to assess the safety and effectiveness of pulmonary artery denervation with the TIVUS™ System in subjects…
- Trial name
- NCT04570228
- Testing
- Pulmonary artery denervation
- Volunteers
- 205 people
- Sponsor
- SoniVie Inc.
Healthy Volunteer
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
The objective of this two part study was to demonstrate safety, tolerability, and pharmacokinetics of RT234 in healthy volunteers.
- Trial name
- NCT05567367
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI), Vardenafil Oral Tablet
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO)…
- Trial name
- MOONBEAM (NCT05587712)
- Testing
- Sotatercept
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
The primary objective of this study is to evaluate the effect of selexipag on the physical activity of patients with pulmonary arterial hypertension (PAH) in their daily life, by using a wearable wrist device (actigraph).
- Trial name
- TRACE (NCT03078907)
- Testing
- Selexipag
- Where
- 39 sites in United States, Austria and 8 more
- Volunteers
- 108 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
This is a multi-center, Phase 2 Long-Term, Open Label Extension (OLE) Study to assess the safety and tolerability of pemziviptadil (PB1046) at an optimally titrated dose.
- Trial name
- VIP Extend (NCT03795428)
- Testing
- Pemziviptadil (PB1046) Injection
- Where
- 16 sites in United States
- Volunteers
- 25 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Hypertension, Pulmonary
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension
Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT00853112
- Testing
- PF-00489791, sildenafil
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Absorption, Distribution, Metabolism and Excretion of BIA 5-1058
the purpose of this study is: to determine the rate and routes of excretion of BIA 5-1058 and the mass balance in urine, feces and exhaled air, after a single oral dose of 400 mg 14C labeled BIA 5 1058 containing 3.7…
- Trial name
- ADME (NCT04991181)
- Testing
- 400 mg BIA 5-1058
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
This is an observational, multicenter, single-day, Phase 2 study. This study will include a 14-day Screening Period and Study Day 1 clinic visit.
- Trial name
- PRN (NCT03888365)
- Testing
- Treprostinil, Non-Treprostinil PAH Medications
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants
This study is designed to describe pulmonary arterial hypertension (PAH) participants in terms of their clinical characteristics, therapies used, disease progression, and outcomes (example, death, hospitalization, risk category…
- Trial name
- CARE PAH (NCT04955990)
- Testing
- PAH Therapies
- Where
- 54 sites in United States, Argentina and 15 more
- Volunteers
- 232 people
- Sponsor
- Actelion